Related Experiment Videos
[Fundamental and clinical studies of cefoperazone in pediatric patients (author's transl)]
Insights
Cefoperazone (CPZ) demonstrated high efficacy in treating infections in infants, with an 85% success rate. This cephalosporin showed a favorable safety profile, comparable to other cephalosporins, with minimal side effects observed.
Area of Science:
- Pharmacology
- Clinical Medicine
- Pediatrics
Context:
- Cefoperazone (CPZ) is a novel cephalosporin developed in Japan.
- Infants aged 2 days to 12 years with various infections were included in the study.
- The study evaluated susceptibility, serum and spinal fluid concentrations, and clinical effects of CPZ.
Purpose:
- To assess the clinical efficacy and safety of cefoperazone in pediatric patients.
- To determine the pharmacokinetic profile of cefoperazone in infants.
- To compare the side effect profile of cefoperazone with other cephalosporins.
Summary:
- Cefoperazone (CPZ) showed a high clinical efficacy rate of 85.0% in 22 infants treated with CPZ alone.
- The mean half-life of CPZ after a single intravenous injection of 25 mg/kg in 3 infants was 80.7 minutes.
- Observed side effects included rash and vascular pain, which resolved upon discontinuation, suggesting a safety profile comparable to other cephalosporins.
Impact:
- Provides evidence for the effectiveness of cefoperazone in treating pediatric infections.
- Offers pharmacokinetic data relevant for dosing cefoperazone in infants.
- Contributes to the understanding of cefoperazone's safety profile in a pediatric population.
Abstract:
1. Susceptibility, concentrations in serum and spinal fluid, and clinical effect of cefoperazone (CPZ), a newly developed cephalosporin in Japan, were examined in 28 infants from 2 days to 12 years of ages with various infections. 2. The overall clinical evaluation in 22 cases received CPZ alone was found to be markedly effective in 11 cases and effective in 6 cases; the efficacy rate was as good as 85.0%. 3. The mean half-life following a single intravenous injection of 25 mg/kg to 3 infants was 80.7 minutes. 4. The side effects observed during the therapy were 2 cases of rash and 1 case of vascular pain and these symptoms improved after interruption of therapy. The side effects of CPZ seemed to be not more noticeable than other cephalosporins.